Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 4/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30272382 | 0.78 | TSHR (0.53) | FKBP1AL3MBTL1POLBTSHRGLA | |
| SCHEMBL9715182 | 0.76 | FKBP1A (0.46) | FKBP1AL3MBTL1POLBTSHRGLA | |
| SCHEMBL21679696 | 0.75 | TSHR (0.54) | FKBP1AL3MBTL1POLBTSHRGLA | |
| SCHEMBL4297789 | 0.75 | POLB (0.58) | FKBP1AL3MBTL1POLBTSHRGLA | |
| SCHEMBL9415751 | 0.74 | GLA (0.67) | FKBP1AL3MBTL1POLBTSHRGLA | |
| SCHEMBL3736506 | 0.74 | TSHR (0.57) | FKBP1AL3MBTL1POLBTSHRGLA | |
| SCHEMBL14079960 | 0.74 | TSHR (0.53) | FKBP1AL3MBTL1POLBTSHRGLA | |
| SCHEMBL3404224 | 0.72 | L3MBTL1 (0.63) | FKBP1AL3MBTL1POLBTSHRGLA | |
| SCHEMBL7694058 | 0.72 | GLA (0.65) | FKBP1AL3MBTL1POLBTSHRGLA | |
| SCHEMBL5778349 | 0.72 | L3MBTL1 (0.57) | FKBP1AL3MBTL1POLBTSHRGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267719-A1 | Enhanced Indolinone Based Protein Kinase Inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-10-21 | — | — | US | disclosed |
| EP-1893194-A4 | ENHANCED INDOLINONE BASED PROTEIN KINASE INHIBITORS | SCRIPPS RESEARCH INST (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-1893194-A1 | ENHANCED INDOLINONE BASED PROTEIN KINASE INHIBITORS | The Scripps Research Institute (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20060287381-A1 | Enhanced indolinone based protein kinase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2006-12-21 | — | — | US | disclosed |
| WO-2006127961-A1 | ENHANCED INDOLINONE BASED PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287381-A1 | Enhanced indolinone based protein kinase inhibitors | PHKG1, PHKG2, PRKCH | FKBP1A 952/4885L3MBTL1 2815/4885POLB 2296/4885 |
| US-20100267719-A1 | Enhanced Indolinone Based Protein Kinase Inhibitors | PHKG1, PHKG2, PRKCH | FKBP1A 1308/4885L3MBTL1 2856/4885POLB 2420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.